1. EVFM reported 10% increase in Q3 2025 net sales to $5.0 million. 2. Operating income reached $1.0 million, contrasting with a prior loss of $2.4 million. 3. Operating expenses decreased by 42% year-over-year, boosting profitability. 4. Cost reductions aim for entry into price-sensitive markets for PHEXXI and SOLOSEC. 5. Merger agreement with Aditxt was terminated after stockholder disapproval on October 20.
The significant reduction in operating expenses and increase in net sales suggest improved financial health for EVFM, akin to past recoveries seen in other small-cap biotech firms. This may drive investor sentiment positively.
The reported improvements and strategic plans for cost reduction indicate that EVFM may build investor confidence, making this report particularly relevant for stock price movement.
The immediate responses to EVFM's financial results could influence stock performance shortly, similar to past quarterly earnings reports spurring quick market movements.
-- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO, Nov. 13, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update.
EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">
"Sales rebounded in the third quarter and were 10% higher than the same quarter last year, reflecting the joint effort of our sales team combined with our smart, provocative social media initiatives and the great press coverage we garnered this summer," said Saundra Pelletier, CEO of Evofem Biosciences.
Notable developments since July 1st include:
Third Quarter Financial Results
For the three months ended September 30, 2025, net sales were $5.0 million compared to $4.5 million in the prior year period. The increase reflects the impact of the PHEXX wholesale average cost (WAC) increase that took effect on January 1, 2025, a slight increase in PHEXX ex-factory unit sales, and a full quarter of SOLOSEC net sales in the current year period.
Total operating expenses decreased to $4.0 million in the third quarter of 2025, versus $6.9 million in the prior year period. The $2.9 million improvement was driven by a $1.0 million decrease in general and administrative expenses in the current year quarter and a one-time gain of $1.9 million due to a change in the accounting estimates related to the contingent Rush royalty liability because of the now-expired Rush patent.
As a result, Evofem reported $1.0 million of operating income for the third quarter of 2025, versus a loss from operations of $2.4 million in the prior year quarter.
Net loss attributable to common stockholders was $1.7 million in the third quarter of 2025, versus a net loss attributable to common stockholders of $2.4 million in the third quarter of 2024. This equates to net loss of $0.01 per basic and diluted share for the third quarter of 2025, versus net loss of $0.02 per basic and diluted share for the third quarter of 2024.
Liquidity
The Company had restricted cash of $0.8 million as of September 30, 2025 as compared to $0.7 million as of December 31, 2024.
About Evofem
Evofem Biosciences is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.
PHEXX®, PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.
Sources
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to Evofem's expectations regarding the anticipated impact of COGS reduction initiatives, future sales trends, cost-reduction initiatives, manufacturing efficiencies, international market expansion, and the Company's ability to obtain additional financing or other strategic alternatives. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, the nonrecurring nature of certain recent gains, together with those that are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 13, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company's current liquidity position and evolving business conditions.
Connect with Us | |
Join the Dialogue | |
@evofem + @saundrapelletier | |
TikTok | @phexxi + @saundrapelletier |
@evofem, @phexxi + @saundrapelletier | |
X | @evofem + @SaundraCEO |
@evofem + @phexxi |
Media
media@evofem.com
Investors and Potential Partners
Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
Financial tables follow
EVOFEM BIOSCIENCES, INC., AND SUBSIDIARIES | |||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||
(unaudited) | |||
(In thousands) | |||
As of | |||
September 30, 2025 | December 31, 2024 | ||
Cash and cash equivalents | $ - | $ - | |
Restricted cash | $ 840 | $ 741 | |
Trade accounts receivable, net | $ 4,435 | $ 9,832 | |
Total current liabilities | $ 78,186 | $ 80,448 | |
Total stockholders' deficit | $ (75,066) | $ (71,257) | |
Total liabilities, convertible and redeemable preferred | $ 13,807 | $ 23,789 | |
EVOFEM BIOSCIENCES, INC., AND SUBSIDIARIES | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
(unaudited) | ||||||||
(In thousands, except share and per share data) | ||||||||
Three Months Ended | Nine Months Ended | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Product sales, net | $ 4,952 | $ 4,496 | $ 10,622 | $ 12,259 | ||||
Operating Expenses: | ||||||||
Cost of goods sold | 905 | 869 | 2,025 | 2,322 | ||||
Gain on change in accounting estimates | (1,933) | - | (1,933) | - | ||||
Amortization of intangible asset | 80 | 301 | 410 | 301 | ||||
Research and development, net | 470 | 332 | (3,819) | 1,196 | ||||
Selling and marketing | 2,391 | 2,382 | 7,616 | 6,970 | ||||
General and administrative | 2,088 | 3,052 | 6,296 | 8,143 | ||||
Total operating expenses | 4,001 | 6,936 | 10,595 | 18,932 | ||||
Income (loss) from operations | 951 | (2,440) | 27 | (6,673) | ||||
Other income (expense): | ||||||||
Interest income | 3 | 3 | 13 | 13 | ||||
Other expense, net | (682) | (562) | (1,944) | (1,736) | ||||
Loss on issuance of financial instruments | - | - | - | (3,300) | ||||
Gain (loss) on debt extinguishment, net | - | (143) | - | 977 | ||||
Change in fair value of financial | (1,845) | 769 | (490) | 4,896 | ||||
Total other income (expense), net | (2,524) | 67 | (2,421) | 850 | ||||
Loss before income tax | (1,573) | (2,373) | (2,394) | (5,823) | ||||
Income tax benefit (expense) | 4 | 8 | (3) | - | ||||
Net loss | (1,569) | (2,365) | (2,397) | (5,823) | ||||
Convertible and redeemable preferred stock | (111) | (5) | (115) | (99) | ||||
Net loss attributable to common stockholders | $ (1,680) | $ (2,370) | $ (2,512) | $ (5,922) | ||||
Net loss per share attributable to common | $ (0.01) | $ (0.02) | $ (0.02) | $ (0.09) | ||||
Weighted-average shares used to compute net | 119,578,093 | 96,459,121 | 116,229,614 | 64,924,454 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-reports-financial-results-for-third-quarter-of-2025-provides-business-update-302615033.html
SOURCE Evofem Biosciences, Inc.